Investment report on Sequenom from MicroStockProfit.com

Apr 20 2010

MicroStockProfit.com announces an investment report featuring Sequenom Inc. (Nasdaq:SQNM). The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/SQNM

Sequenom Inc. (SQNM) provides diagnostic testing services, products and applications that utilize genomic science for biomedical research and molecular diagnostics applications to various markets worldwide. The Company's proprietary MassARRAY system measures genetic target material for DNA analysis. The Company's development and commercialization efforts include solutions in the areas of prenatal diagnostics, age-related macular degeneration diagnostics, oncology, infectious diseases, and other disorders and diseases. 

Message Board Search for SQNM: http://www.boardcentral.com/boards/SQNM

In the report, the analyst notes:

"In the latest 10-Q, the Company said it is developing various noninvasive molecular diagnostic tests relating to women's disorders and disease, age-related disease, oncology, infectious diseases and other maladies. In the area of prenatal diagnostics, the Company has recently branded its diagnostic technology under the SEQureDx trademark. Molecular diagnostics technologies are currently marketed under the MassARRAY brand trademark.

"The Company is primarily focused on the commercialization of a diagnostic testing platform in the areas of prenatal screening. The technology utilizes maternal blood for the non-invasive diagnosing or risk-assessing of the status of a fetus early in pregnancy without the need for invasive procedures such as amniocentesis, chorionic villus sampling, or surgery."